New Haven, Conn. --The Yale BioHaven Entrepreneurship Seminars series begins its fall schedule on Wednesday, September 20 from 3:30 to 5 p.m. in the Anlyan Center Auditorium of Yale Medical School, 300 Cedar Street.

This program will feature TheraLogics, Inc., a technology start-up company that is unusual because it has not received -- and is not seeking -- venture capital investments. Rather, it is funded through licensing agreements of technology previously developed by one co-founder of the company. TheraLogics also anticipates participating in a non-profit foundation as a potential source of research revenue.

Speakers are Max Wallace, the C.E.O. of TheraLogics and former C.E.O. of Trimeris Pharmaceuticals; and Sankar Ghosh, professor of immunobiology, and molecular biophysics & biochemistry at Yale University and co-founder of TheraLogics.

Many major human diseases, including arthritis, asthma, colitis, and cancer can be attributed to problems related to regulation of the transcription factor NF-kB. The goal of TheraLogics is to develop effective inhibitors of NF-kB and to bring these drugs into the clinical arena by establishing a network of investigators in academia and biopharm, who are each focusing on one of the major NF-kBrelevant target diseases.

Wallace and Ghosh will discuss how they have managed to move from basic research to applying a technology rapidly, even though TheraLogics has yet to make itself visible on the web or with a physical research facility. Their intention is to show potential academic founders and entrepreneurs a new model for translating technologies.

Refreshments and networking will follow the seminar from 5 to 7 p.m. Registration is free, but advance RSVP to Larry Banks at larry.banks@yale.edu or the Yale Office of Cooperative Research at 203-436-8096 is required. Directions to the event are available on line at

Contact: Janet Rettig Emanuel
janet.emanuel@yale.edu
203-432-2157
Yale University
14-Sep-2006